Back to top
more

Tandem Diabetes Care (TNDM)

(Delayed Data from NSDQ)

$15.40 USD

15.40
1,385,256

-0.18 (-1.16%)

Updated Aug 1, 2025 04:00 PM ET

After-Market: $15.39 -0.01 (-0.06%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth F Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 36% (158 out of 246)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Will Stereotaxis Inc. (STXS) Report Negative Earnings Next Week? What You Should Know

by Zacks Equity Research

Stereotaxis (STXS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Tandem Diabetes Care, Inc. (TNDM) Expected to Beat Earnings Estimates: Should You Buy?

by Zacks Equity Research

Tandem Diabetes Care (TNDM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Down 27.0% in 4 Weeks, Here's Why You Should You Buy the Dip in Tandem Diabetes Care (TNDM)

by Zacks Equity Research

The heavy selling pressure might have exhausted for Tandem Diabetes Care (TNDM) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Zacks Equity Research

TNDM Stock Gains on t:slim X2's Compatibility With FreeStyle Libre 3 +

by Zacks Equity Research

Tandem Diabetes' t:slim X2 pump with Control-IQ+ tech gains U.S. early access using FreeStyle Libre 3 Plus sensor.

Zacks Equity Research

Tandem Diabetes Care (TNDM) Up 6.5% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Tandem Diabetes Care (TNDM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Should Tandem Diabetes Stock Stay in Your Portfolio Now?

by Zacks Equity Research

Investors remain optimistic about TNDM, courtesy of its strong t:slim X2 performance and breakthrough innovations.

Zacks Equity Research

TNDM Stock Rises Despite Q1 Earnings Miss, Gross Margin Up

by Zacks Equity Research

Tandem Diabetes' Q1 bottom line lags estimate. However, the company experiences strong sales growth both in and outside the United States.

Zacks Equity Research

Tandem Diabetes Care (TNDM) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates

by Zacks Equity Research

Although the revenue and EPS for Tandem Diabetes Care (TNDM) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Zacks Equity Research

Tandem Diabetes Care, Inc. (TNDM) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Tandem Diabetes Care (TNDM) delivered earnings and revenue surprises of -11.67% and 6.44%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

What to Expect From These 3 MedTech Stocks This Earnings Season?

by Zacks Equity Research

Here is a sneak peek into how these three MedTech stocks, ALGN, TNDM and ICLR, may fare in their quarterly results, slated to be released tomorrow.

Zacks Equity Research

Penumbra (PEN) Q1 Earnings and Revenues Top Estimates

by Zacks Equity Research

Penumbra (PEN) delivered earnings and revenue surprises of 25.76% and 2.67%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Reasons to Hold TNDM Stock in Your Portfolio for Now

by Zacks Equity Research

A robust diabetes market and international expansion raise investors' optimism for Tandem Diabetes.

Urmimala Biswas headshot

Tap Into the Silver Economy Boom With These Aging Demographics Stocks

by Urmimala Biswas

The global demographic shift is reshaping healthcare demand, driving long-term investment in pharmaceuticals, medical devices, home care and digital health.

Zacks Equity Research

Tandem Diabetes Care (TNDM) Moves 7.6% Higher: Will This Strength Last?

by Zacks Equity Research

Tandem Diabetes Care (TNDM) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Zacks Equity Research

Tandem Diabetes Care (TNDM) Down 8.9% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Tandem Diabetes Care (TNDM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

TNDM Stock Gains on the Commercial Launch of Control-IQ+ Technology

by Zacks Equity Research

Tandem Diabetes launches Control-IQ+ technology commercially in the United States. Control-IQ+ is compatible with t:slim X2 insulin pump and Tandem Mobi System.

Zacks Equity Research

Reasons to Hold TNDM Stock in Your Portfolio for Now

by Zacks Equity Research

A robust product innovation and several strategic developments raise investors' optimism for Tandem Diabetes.

Zacks Equity Research

TNDM Stock Falls in Aftermarket Following Q4 Earnings and Revenue Miss

by Zacks Equity Research

Tandem Diabetes' Q4 top and bottom lines lag their respective estimate. However, the company experiences strong sales growth both in and outside the United States.

Zacks Equity Research

Here's What Key Metrics Tell Us About Tandem Diabetes Care (TNDM) Q4 Earnings

by Zacks Equity Research

While the top- and bottom-line numbers for Tandem Diabetes Care (TNDM) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Zacks Equity Research

Tandem Diabetes Care, Inc. (TNDM) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research

Tandem Diabetes Care (TNDM) delivered earnings and revenue surprises of -76% and 1.07%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Tandem Diabetes Care (TNDM) Q4 Earnings on the Horizon: Analysts' Insights on Key Performance Measures

by Zacks Equity Research

Evaluate the expected performance of Tandem Diabetes Care (TNDM) for the quarter ended December 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.

Zacks Equity Research

NeuroPace (NPCE) Surges 5.8%: Is This an Indication of Further Gains?

by Zacks Equity Research

NeuroPace (NPCE) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Zacks Equity Research

Tactile Systems Technology (TCMD) Tops Q4 Earnings and Revenue Estimates

by Zacks Equity Research

Tactile Systems Technology (TCMD) delivered earnings and revenue surprises of 21.21% and 0.18%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Tandem Diabetes Gains 45.7% in a Year: What's Driving the Stock?

by Zacks Equity Research

TNDM's shares rise as its expanding product portfolio gains market traction. However, the unfavorable macroeconomic scenario is concerning.

Zacks Equity Research

Is SPDR S&P Health Care Equipment ETF (XHE) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for XHE